Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07444814 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
A Phase 1 study of Ovarian Cancer and Endometrial Cancer, sponsored by Whitehawk Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 226
- Enrollment target
- 12
- Study locations
NCT07444814 is a Phase 1 study of Ovarian Cancer and Endometrial Cancer that is actively recruiting participants, run by Whitehawk Therapeutics. The registered enrollment target is 226 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (69% lower). The trial reports 12 study locations across 10 states.
The verdict
NCT07444814, a Phase 1 study of Ovarian Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by Whitehawk Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 226 participants
- Enrollment target
- 12
- Study locations
Study Summary
HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose escalation and dose expansion design without a control group.
Conditions Studied
Interventions
- DRUG HWK-007
Study Locations (12)
Texas
- NEXT Oncology - Austin - Austin
- NEXT - Oncology - Houston - Houston
- START - San Antonio - San Antonio
Arkansas
- University of Arkansas - Little Rock
California
- UCLA - Hematology/Oncology Clinical Research Unit - Los Angeles
Illinois
- St. Francis Medical Center (OSF Healthcare) - Peoria
Michigan
- START - Midwest - Grand Rapids
New Jersey
- Hackensack University Medical Center - John Theurer Cancer Center - Hackensack
New York
- Roswell Park Comprehensive Care Center - Buffalo
Ohio
- University Hospital - Cleveland Medical Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2025-12-19 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07444814
The ClinicalTrials.gov registry entry for NCT07444814 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (69% lower). The listed sponsor is Whitehawk Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which HWK-007 is the first listed.
NCT07444814 reports 12 study locations spanning 10 distinct geographic areas - top geographies include Texas, Arkansas, California.
Frequently Asked Questions
What is clinical trial NCT07444814 about?
NCT07444814 is a clinical study titled "Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors". HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose ...
What is the current status of trial NCT07444814?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 226 participants. The study started on 2025-12-19. Estimated completion is 2028-12.
What conditions does trial NCT07444814 study?
This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Platinum-resistant Ovarian Cancer, PROC, Ovarian Cancer Metastatic.
What interventions are being tested in trial NCT07444814?
The interventions under investigation include: HWK-007 (DRUG).
Who is sponsoring clinical trial NCT07444814?
This trial is sponsored by Whitehawk Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07444814 being conducted?
This trial has 12 study locations across Arkansas, California, Illinois, Michigan, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.